BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Ariad Pharmaceuticals, Inc. (NQ: ARIA)
7.200 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(ARIA) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 18, 2014
(Stock Blog Hub, 5/15/13)
Ariad Pharmaceuticals, Inc. (ARIA) reported first quarter loss of 36 cents per share, wider than the year-ago loss of 25 cents per share but narrower than the Zacks...(read more)
(Stock Blog Hub, 4/21/13)
Ariad Pharmaceuticals, Inc. (ARIA) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant...(read more)
(market folly, 4/30/12)
Steve Cohen's hedge fund SAC Capital filed a 13G with the SEC regarding its ownership stake in Ariad Pharmaceuticals (ARIA).  SAC now owns 4.9% of the company with 7,876,700 shares. This is a 208%...(read more)
ARIAD Pharmaceuticals (ARIA) Company Overview

There is no analysis for ARIA yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here